Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

Revenio Group

18.60 EUR

+0.98 %

14,244 following
Corporate customer

REG1V

NASDAQ Helsinki

Medical Equipment & Services

Health Care

+0.98 %
-13.29 %
-16.96 %
-16.78 %
-25.45 %
-31.52 %
-49.57 %
-66.12 %
+878.95 %

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand. In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Read more
Market cap
496.27M EUR
Turnover
824.93K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Buy
Target price
Updated
12.02.2026
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Latest research

Latest analysis report

Released: 12.02.2026

Latest extensive report

Released: 21.01.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
15.4.
2026

General meeting '26

28.4.
2026

Interim report Q1'26

6.8.
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Revenio Q4'25 preview: Valuation reaches historic lows
Research by
Juha Kinnunen

Revenio Q4'25 preview: Valuation reaches historic lows

Revenio's valuation has fallen to a historically low level, as the industry faces concerns, especially after Zeiss's grim profit warning. We consider the concerns regarding Revenio to be exaggerated and estimate the company's earnings to be firmly on an upward trend this year.

Revenio Group
Revenio Q3'25: Q4 will decide this year too
Research by
Juha Kinnunen

Revenio Q3'25: Q4 will decide this year too

Revenio's Q3 earnings fell short of our overly optimistic expectations, but on the other hand, the Q4 outlook appears better than we anticipated. There have been no dramatic revisions in the outlook for the coming years, but the market is showing at least small signs of recovery.

Revenio Group
Forum discussions
Revenio has really started to look interesting after the massive correction in its stock price and valuation multiples. I know as much about intraocular pressure monitors as a pig knows about football, but the technology is apparently still world-class. The outlook is said to be ...
2/13/2026, 10:35 AM
by Ituhippinen
54
This has been discussed here at regular intervals. In my opinion, the most viable candidate is Demant, which is already a clear major shareholder (24.48%) and could practically block other suitors. However, Demant likely doesn’t want to take Revenio off the exchange entirely; instead...
2/18/2026, 5:10 PM
by Juha Kinnunen
43
I’ve been thinking the same, but if I recall correctly, insiders aren’t allowed to trade when acquisition negotiations are ongoing. Revenio has publicly commented on exploring M&A opportunities, and apparently, expenses from these investigations have been recorded in recent years...
2/13/2026, 10:53 AM
by Tyhjätasku
33
I think of it this way: recurring revenue can grow by any amount, but its relative development compared to total revenue is dependent on how much device sales grow. So, if recurring revenue grows strongly in relative terms, it might even be concerning, as it would indicate that device...
2/15/2026, 5:04 PM
by Tyhjätasku
31
Greetings to the thread. I’ve jumped back on board again. I have cashed out twice from this over the last 9 years. Time will tell how it goes this time. Reasons for getting back in now: low valuation combined with interesting prospects despite the antics of US politicians the ongoing...
2/13/2026, 1:34 PM
by M
26
I recalled that Revenio mentioned in its 2024 annual report that “recurring” revenue—i.e., revenue from the sale of software, sensors, and service contracts—was “nearly a third,” and indeed it was. Now it was mentioned that this same share again accounted for “nearly a third.” It...
2/15/2026, 3:07 PM
by Anonyymi123
20
How does @Juha_Kinnunen see Revenio itself as an acquisition target? There has been an accelerating trend of M&A in the industry over the past couple of years, and Revenio is still a fairly small player compared to many of the giants in its peer group. At the same time, Revenio is...
2/18/2026, 9:04 AM
by MTES
11
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.